APOKYN (apomorphine)
INITIATION DOSE IS OFFICE ADMINISTERED: SUBCUTANEOUS INJECTION
Indication(s) for Prior Authorization:
- Parkinson’s Disease, treatment of hypomobility
Patients must meet all the following criteria for the indication above:
- Adjunctive treatment for patients with advanced Parkinson’s Disease experiencing acute hypomobility secondary to end-of-dose wearing off episodes or unpredictable off episodes
- Prescribed or recommended by a neurologist
- Must be on concurrent therapy with: carbidopa-levodopa (Sinemet ®) at the maximum tolerated dose and a second agent such as a MAO-B inhibitor, Dopamine Agonist or COMT inhibitor
- Concurrent therapy with trimethobenzamide (Tigan) – 3 days prior to initiation and continued for at least 2 months after apomorphine
- Contraindicated in patients who are currently taking 5HT3 antagonists
The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:
- Any Indication not listed above
Dosing:
- Up to 0.6 ml (6 mg) subcutaneously
Last review date: December 1, 2014